N.V. REZOVA, A.V. BUDNEVSKIY, A.Ya. KRAVCHENKO, A.V. PERTSEV, A.A. FESKOVA

Voronezh State Medical University named after N.N. Burdenko, Voronezh

Contact details:

Rezova N.V. ― postgraduate student of the Department of Faculty Therapy

Address: 10 Studencheskaya Str., Voronezh, Russian Federation, 394036, (473) 263-81-30, e-mail: filina.nadyusha@mail.ru

 Objective ― to study the pathogenetic features of arterial hypertension in patients with sleep disorders depending on the level of melatonin sulfate in the urine and the parameters of thyroid status.

Materials and methods. The study involved 90 patients aged 59.4±6.5 years treated at Cardiology Departments with a diagnosis of hypertension of 1-3 degrees. All patients underwent clinical examination including: general blood test, general urine test, biochemical blood test, echocardiography, daily monitoring of blood pressure, testing the quality of sleep by PSQI, and determining melatonin sulfate in the morning urine and examination of thyroid status.

Results and discussion. The revealed interrelations of thyroid status with the indicators of daily blood pressure suggest the influence of thyroid hormones on the regulation of vascular tone through the impact on the pressor and depressor mechanisms. The use of melatonin drugs in conjunction with the main antihypertensive therapy would allow correcting sleep disorders in patients with hypertension and enhancing the effectiveness of hypertension therapy.

Key words: blood pressure, melatonin, thyroid-stimulating hormone, sleep disorders.

REFERENCES

1. Budnevskiy A.V., Ovsyannikov E.S., Filina N.V. The role of melatonin in the pathogenesis of cardiovascular diseases. Kardiovaskulyarnaya terapiya i profilaktika, 2016, no. 5, pp. 97-101 (in Russ.).
2. Chazova I.E., Zhernakova Yu.V. Recommendations for the diagnosis and treatment of arterial hypertension in 2018 — a word for European experts. Sistemnye gipertenzii, 2018, vol. 15, no. 3, pp. 6-10 (in Russ.).
3. Boytsov S.A., Balanova Yu.A., Shal’nova S.A. et al. Arterial hypertension among persons aged 25-64: prevalence, awareness, treatment and control. Based on the ESSE study materials. Kardiovaskulyarnaya terapiya i profilaktika, 2014, vol. 13, no. 4, pp. 4-14 (in Russ.).
4. Budnevskiy A.V., Ovsyannikov E.S., Rezova N.V. et al. Melatonin and arterial hypertension: a possible role in the complex therapy. Terapevticheskiy arkhiv, 2017, vol. 89, no. 12, pp. 122-126 (in Russ.).
5. Verbovoy A.F. et al. Hypothyroidism and cardiovascular diseases. Farmateka, 2015, vol. 17, no. 310, pp. 36-41 (in Russ.).
6. Budnevskiy A.V., Burlachuk V.T., Grekova T.I. Hypothyroidism and cardiovascular pathology. Meditsinskiy nauchnyy i uchebno-metodicheskiy zhurnal, 2007, no. 38, p. 80 (in Russ.).
7. Fes’kova A.A., Kravchenko A.Ya. Interrelation of thyroid status and indices of daily monitoring of arterial pressure in patients with arterial hypertension. Farmateka, 2018, no. 10 (363), pp. 43-45 (in Russ.).
8. Raskina E.A., Sergeev I.A., Fes’kova A.A. et al. Features of the course of arterial hypertension against the background of subclinical hypothyroidism. Natsional’noe zdorov’e, 2018, no. 2, pp. 143-149 (in Russ.).